Literature DB >> 10690383

A clinical model for quality of life assessment in cancer patients receiving chemotherapy.

M C Klee1, M T King, D Machin, H H Hansen.   

Abstract

BACKGROUND: The pattern of symptoms experienced by cancer patients during chemotherapy is very complex. Consequently, quality of life (QOL) assessment has to be carefully planned to capture clinically relevant changes. PATIENTS AND METHODS: A clinical model of changes in symptoms experienced by symptomatic metastatic patients during several courses of chemotherapy has been developed. The model differentiates cancer-related symptoms, acute side-effects, chronic side-effects and symptoms not related to cancer. The model was used to predict changes in each of these four symptom groups. Three time points were selected (post-cycle 2, pre-cycle 3, post-cycle 5) and an appropriate window around each time point was set. The model predictions were tested empirically with 56 patients with advanced ovarian cancer who completed the EORTC QLQ-C30 plus disease specific items during a six-cycle course of chemotherapy.
RESULTS: The changes observed in the sample were in accordance with the changes predicted by the clinical model. Results from patients who did not complete the questionnaire within the specified time windows tended to dilute the findings from the group who did.
CONCLUSIONS: A clinical model is useful in the planning of QOL assessments in order to capture clinically relevant effects. Such models also facilitate the interpretation of QOL studies, particularly when cyclic short-term effects and chronic side-effects are overlaid on disease symptoms, as is the case with chemotherapy for cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10690383     DOI: 10.1023/a:1008394107982

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  8 in total

1.  Effect of completion-time windows in the analysis of health-related quality of life outcomes in cancer patients.

Authors:  D E Ediebah; C Coens; J T Maringwa; C Quinten; E Zikos; J Ringash; M King; C Gotay; H-H Flechtner; J Schmucker von Koch; J Weis; E F Smit; C-H Köhne; A Bottomley
Journal:  Ann Oncol       Date:  2012-08-30       Impact factor: 32.976

2.  Quality of life as a clinical trial endpoint: determining the appropriate interval for repeated assessments in patients with advanced lung cancer.

Authors:  Patricia J Hollen; Richard J Gralla; Cynthia N Rittenberg
Journal:  Support Care Cancer       Date:  2004-11       Impact factor: 3.603

Review 3.  Health-related quality of life in patients with brain tumors: limitations and additional outcome measures.

Authors:  Linda Dirven; Jacob C Reijneveld; Neil K Aaronson; Andrew Bottomley; Bernard M J Uitdehaag; Martin J B Taphoorn
Journal:  Curr Neurol Neurosci Rep       Date:  2013-07       Impact factor: 5.081

4.  Health - related quality of life of Kuwaiti women with breast cancer: a comparative study using the EORTC Quality of Life Questionnaire.

Authors:  Shafika A Alawadi; Jude U Ohaeri
Journal:  BMC Cancer       Date:  2009-07-08       Impact factor: 4.430

5.  Meta-analysis provides evidence-based interpretation guidelines for the clinical significance of mean differences for the FACT-G, a cancer-specific quality of life questionnaire.

Authors:  Madeleine T King; David Cella; David Osoba; Martin Stockler; David Eton; Joanna Thompson; Amy Eisenstein
Journal:  Patient Relat Outcome Meas       Date:  2010-09-23

6.  Factors associated with quality of life of outpatients with breast cancer and gynecologic cancers and their family caregivers: a controlled study.

Authors:  Abdel W Awadalla; Jude U Ohaeri; Abdullah Gholoum; Ahmed O A Khalid; Hussein M A Hamad; Anila Jacob
Journal:  BMC Cancer       Date:  2007-06-19       Impact factor: 4.430

7.  Assessing quality of life on the day of chemotherapy administration underestimates patients' true symptom burden.

Authors:  Johannes M Giesinger; Lisa M Wintner; August Zabernigg; Eva-Maria Gamper; Anne S Oberguggenberger; Monika J Sztankay; Georg Kemmler; Bernhard Holzner
Journal:  BMC Cancer       Date:  2014-10-10       Impact factor: 4.430

8.  Strategies to improve patient-reported outcome completion rates in longitudinal studies.

Authors:  Lene Kongsgaard Nielsen; Madeleine King; Sören Möller; Mary Jarden; Christen Lykkegaard Andersen; Henrik Frederiksen; Henrik Gregersen; Anja Klostergaard; Morten Saaby Steffensen; Per Trøllund Pedersen; Maja Hinge; Mikael Frederiksen; Bo Amdi Jensen; Carsten Helleberg; Anne Kærsgaard Mylin; Niels Abildgaard
Journal:  Qual Life Res       Date:  2019-09-23       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.